Latanoprost clinical trials
Also written Xalatan, T2345 and PhXA41.
How each study uses Latanoprost is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Latanoprost studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 Jun 1996 · XALATAN · NDA 020597 (FDA, Drugs@FDA)
- European Union
- 7 Jan 2021 · Roclanda · EMEA/H/C/005107 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
96 studies that test it; most in 2009 (10)
| Year | Studies |
|---|---|
| 1992 | 2 |
| 1993 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 4 |
| 2005 | 7 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 9 |
| 2009 | 10 |
| 2010 | 7 |
| 2011 | 6 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 52 · Other 47
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Mati Therapeutics Inc. (8) · Allergan (6) · Alcon Research (4) · Laboratoires Thea (3) · Pfizer (3) · Zagazig University (2) · University of Nebraska (2)
Often tested with
Tested in the same studies.
Timolol (14) · Travoprost (14) · Bimatoprost (11) · Dorzolamide (7) · Brimonidine (5) · Xalacom (3) · Tafluprost (2) · Brinzolamide (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Latanoprost.
- Dec 2026Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet CellsPhase 4 · Rigshospitalet, Denmark
- Mar 2027Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma SuspectsPhase 4 · University of Maryland, Baltimore
Studies
Open first, then newest update. How each study uses Latanoprost is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 99
- Optic Nerve Head Strain in Non-glaucoma SubjectsRecruitingEarly Phase 1Johns Hopkins UniversityNCT07425535Written as Latanoprost (0.005%)How we know
- Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma SuspectsRecruitingPhase 4University of Maryland, BaltimoreNCT04401982Written as Latanoprost (0.005%)How we know
- 0.005% Latanoprost Gel for Nonsegmental VitiligoNot yet recruitingPhase 2Universitas PadjadjaranNCT07016113Written as 0.005% latanoprost gelHow we know
- Evaluation of Latanoprost Combined With Fractional Erbium- YAG LaserRecruitingPhase 1/2EgymedicalpediaNCT06239324Written as LatanoprostHow we know
- Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet CellsRecruitingPhase 4Rigshospitalet, DenmarkNCT04957329Written as XalatanHow we know
- Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia AreataCompletedNot applicableTanta UniversityNCT07757867Written as LatanoprostHow we know
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure VarianceCompletedPhase 4Ohio State UniversityNCT04412096Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- Stop Retinal Ganglion Cell Dysfunction StudyTerminatedPhase 3University of MiamiNCT02390284Written as LatanoprostHow we know
- Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Nicox Ophthalmics, Inc.NCT04445519Written as Latanoprost 0.005% (initial phase of trial)How we know
- Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin TartrateCompletedEarly Phase 1Zagazig UniversityNCT06730516Written as Latanoprost (Xalatan)How we know
- Effect of Latanoprost on Optic Nerve PerfusionCompletedPhase 1Zagazig UniversityNCT06629129Written as Latanoprost (0.005%)How we know
- Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionCompletedPhase 2Laboratoires TheaNCT01494753Written as T2345How we know
- Comparison of Latanoprost Vs. TimololTerminatedPhase 2University of NebraskaNCT00579969Written as LatanoprostHow we know
- Circadian Rhythms of Aqueous Humor Dynamics in HumansCompletedPhase 2University of NebraskaNCT00572936Written as LatanoprostHow we know
- Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory EvaluationActive, not recruitingPhase 4Shaimaa Fawzy Abdel-rady Abdel-latifNCT04811326Written as LatanoprostHow we know
- Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.CompletedPhase 2/3South Valley UniversityNCT05513924Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical FormulationStatus unknownEarly Phase 1Aneira Pharma, Inc.NCT05790941Written as Latanoprost and MinoxidilHow we know
- Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.Status unknownPhase 4Uzoma Chinyei JoanNCT05606796Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).CompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00383019Written as XalatanHow we know
- Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.CompletedPhase 2PfizerNCT00572455Written as Latanoprost 0.005%How we know
See all 99 studies that test Latanoprost →
Given beside what is tested · 14 — Latanoprost is usual care or a partner of the new treatment
- Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionActive, not recruitingPhase 2PolyActiva Pty LtdNCT06964191Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle GlaucomaCompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT04405245Written as Latanoprost ophthalmic solutionHow we know
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329CompletedPhase 2PfizerNCT00934089Written as latanoprostHow we know
- A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 1Hoffmann-La RocheNCT03293992Written as Latanoprost 0.005%How we know
- Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension SubjectsCompletedPhase 4AllerganNCT00735449Written as latanoprost 0.005%How we know
- Microneedling and Latanoprost in Acrofacial VitiligoStatus unknownPhase 2/3Sohag UniversityNCT03611348Written as LatanoprostHow we know
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).CompletedPhase 1Hoffmann-La RocheNCT02622334Written as LatanoprostHow we know
- A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaCompletedPhase 2Inotek Pharmaceuticals CorporationNCT01917383Written as LatanoprostHow we know
- Safety Study of Latanoprost Slow Release InsertTerminatedPhase 1Daniel MooreNCT01180062Written as LatanoprostHow we know
- Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyCompletedPhase 4Alcon ResearchNCT01263444Written as Habitual prostaglandin monotherapyHow we know
- AR-12286 in Combination With LatanoprostCompletedPhase 2Aerie PharmaceuticalsNCT01302249Written as Latanoprost 0.005%How we know
- A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a ProstaglandinCompletedPhase 4Alcon ResearchNCT00759941Written as Latanoprost 0.005% ophthalmic solution (Xalatan)How we know
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionCompletedPhase 4AllerganNCT01525173Written as latanoprost 0.005% ophthalmic solutionHow we know
- Adjunctive Study of AL-37807 Ophthalmic SuspensionCompletedPhase 2Alcon ResearchNCT00620256Written as Latanoprost ophthalmic solutionHow we know
As the comparator · 63 — what is tested is compared with Latanoprost
- Rocklatan vs Latanoprost Post-DSLTRecruitingPhase 4Eye Centers of Southeast TexasNCT07465913Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension PatientsRecruitingPhase 4Mayo ClinicNCT07325240Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- Efficacy of Simbrinza and Rocklatan vs Cosopt and LatanoprostRecruitingPhase 4Prairie Eye CenterNCT06883123Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- Next Generation RocklatanCompletedPhase 2Alcon ResearchNCT06441643Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2/3Qlaris Bio, Inc.NCT07354516Written as Latanoprost (0.005%)How we know
- A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaActive, not recruitingPhase 3Santen Pharmaceutical Co., Ltd.NCT06666855Written as LatanoprostHow we know
- MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Nicox Ophthalmics, Inc.NCT04630808Written as Latanoprost 0.005%How we know
- OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese SubjectsCompletedPhase 3Otsuka Beijing Research InstituteNCT05583474Written as 0.005% LatanoprostHow we know
- A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen SASNCT04133311Written as Xalatan®How we know
- Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular HypertensionSuspendedPhase 1/2JeniVision, Inc.NCT04761705Written as Latanoprost 0.005% Ophthalmic SolutionHow we know
- A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT02981446Written as Latanoprost ophthalmic solutionHow we know
- A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT05495061Written as Latanoprost ophthalmic solution 0.005%How we know
- Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2Nicox Ophthalmics, Inc.NCT03657797Written as Latanoprost 0.005%How we know
- Nailfold Capillary Blood Flow With Latanoprost BunodCompletedPhase 4Icahn School of Medicine at Mount SinaiNCT03949244Written as Latanoprost 0.005%How we know
- African Glaucoma Laser TrialWithdrawnPhase 4West Virginia UniversityNCT03648229Written as Latanoprost ophthalmic solutionHow we know
- A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In PatientsCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00856622Written as latanoprost 0.005% ophthalmic solutionHow we know
- A Study of Glaucoma or Ocular Hypertension in Patients Within the United StatesCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00800267Written as latanoprost 0.005%How we know
- Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved LatanoprostCompletedPhase 4CHA UniversityNCT04743622Written as XalatanHow we know
- Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular HypertensionCompletedPhase 1/2Novartis PharmaceuticalsNCT00846989Written as LatanoprostHow we know
- POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle GlaucomaCompletedPhase 2Peregrine OphthalmicNCT02466399Written as Latanoprost ophthalmic solutionHow we know
Showing 20 of 63.
Codes
What other systems call Latanoprost · ClinicalTrials.gg INT006705
- MeSH (NLM) D000077338LatanoprostConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6Z5B6HVF6OLATANOPROSTConfirmed FDA, NLM, Wikidata
- RxNorm 43611Confirmed FDA, Wikidata
- Wikidata Q634959latanoprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29151LatanoprostOne source FDA
- DrugBank DB00654One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077338 | Latanoprost | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6Z5B6HVF6O | LATANOPROST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 43611 | — | Confirmed FDA, Wikidata |
| Wikidata | Q634959 | latanoprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29151 | Latanoprost | One source FDA |
| DrugBank | DB00654 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.